Sotera Health Company

NasdaqGS:SHC Stock Report

Market Cap: US$4.8b

Sotera Health Valuation

Is SHC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SHC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SHC ($16.59) is trading below our estimate of fair value ($24.61)

Significantly Below Fair Value: SHC is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SHC?

Other financial metrics that can be useful for relative valuation.

SHC key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue6.3x
Enterprise Value/EBITDA12.8x
PEG Ratio2.4x

Price to Earnings Ratio vs Peers

How does SHC's PE Ratio compare to its peers?

The above table shows the PE ratio for SHC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average38.8x
SYNH Syneos Health
62.6x33.7%US$4.5b
STVN Stevanato Group
40.7x18.3%US$5.6b
CRL Charles River Laboratories International
23.1x12.7%US$10.4b
BRKR Bruker
28.9x20.8%US$10.3b
SHC Sotera Health
117.6x48.2%US$4.8b

Price-To-Earnings vs Peers: SHC is expensive based on its Price-To-Earnings Ratio (117.6x) compared to the peer average (30.9x).

Price to Earnings Ratio vs Industry

How does SHC's PE Ratio compare vs other companies in the US Life Sciences Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a18.0%
 n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a18.0%
 n/an/an/a
No more companies

Price-To-Earnings vs Industry: SHC is expensive based on its Price-To-Earnings Ratio (117.6x) compared to the Global Life Sciences industry average (33x).

Price to Earnings Ratio vs Fair Ratio

What is SHC's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SHC PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio117.6x
Fair PE Ratio45.3x

Price-To-Earnings vs Fair Ratio: SHC is expensive based on its Price-To-Earnings Ratio (117.6x) compared to the estimated Fair Price-To-Earnings Ratio (45.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SHC forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$16.59
US$16.36
-1.4%
7.8%US$18.00US$14.00n/a7
Sep ’25US$15.44
US$16.36
+5.9%
7.8%US$18.00US$14.00n/a7
Aug ’25US$13.63
US$14.79
+8.5%
12.2%US$17.00US$12.00n/a7
Jul ’25US$11.58
US$14.79
+27.7%
12.2%US$17.00US$12.00n/a7
Jun ’25US$11.18
US$14.71
+31.6%
12.4%US$17.00US$12.00n/a7
May ’25US$11.27
US$16.67
+47.9%
12.8%US$20.00US$14.00n/a6
Apr ’25US$11.70
US$17.92
+53.1%
9.2%US$20.00US$15.50n/a6
Mar ’25US$14.56
US$17.83
+22.5%
9.9%US$20.00US$15.00n/a6
Feb ’25US$15.32
US$16.83
+9.9%
10.5%US$20.00US$15.00n/a6
Jan ’25US$16.85
US$16.50
-2.1%
11.5%US$20.00US$15.00n/a6
Dec ’24US$14.00
US$16.42
+17.3%
12.0%US$20.00US$14.50n/a6
Nov ’24US$12.87
US$19.17
+48.9%
10.2%US$21.00US$15.00n/a6
Oct ’24US$14.98
US$20.00
+33.5%
6.5%US$22.00US$18.00n/a6
Sep ’24US$16.00
US$20.43
+27.7%
7.8%US$23.00US$18.00US$15.447
Aug ’24US$18.84
US$19.29
+2.4%
15.4%US$24.00US$16.00US$13.637
Jul ’24US$18.84
US$19.29
+2.4%
15.4%US$24.00US$16.00US$11.587
Jun ’24US$14.19
US$18.50
+30.4%
13.1%US$23.00US$16.00US$11.186
May ’24US$16.41
US$19.50
+18.8%
12.1%US$24.00US$17.00US$11.276
Apr ’24US$17.91
US$19.67
+9.8%
12.7%US$24.00US$17.00US$11.706
Mar ’24US$17.08
US$17.83
+4.4%
30.3%US$24.00US$7.00US$14.566
Feb ’24US$18.26
US$14.50
-20.6%
51.4%US$25.00US$7.00US$15.326
Jan ’24US$8.33
US$7.00
-16.0%
11.7%US$8.00US$6.00US$16.856
Dec ’23US$8.79
US$7.00
-20.4%
11.7%US$8.00US$6.00US$14.006
Nov ’23US$6.90
US$13.50
+95.7%
50.6%US$25.00US$8.00US$12.876
Oct ’23US$6.82
US$18.50
+171.3%
37.2%US$25.00US$9.00US$14.986
Sep ’23US$17.09
US$24.57
+43.8%
11.3%US$30.00US$21.00US$16.007

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y